Orexo AB (publ)
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company i… Read more
Orexo AB (publ) (ORXOF) - Net Assets
Latest net assets as of December 2025: $490.60 Million USD
Based on the latest financial reports, Orexo AB (publ) (ORXOF) has net assets worth $490.60 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.30 Billion) and total liabilities ($812.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $490.60 Million |
| % of Total Assets | 37.66% |
| Annual Growth Rate | 6.15% |
| 5-Year Change | 40.33% |
| 10-Year Change | 58.11% |
| Growth Volatility | 103.64 |
Orexo AB (publ) - Net Assets Trend (2015–2025)
This chart illustrates how Orexo AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Orexo AB (publ) (2015–2025)
The table below shows the annual net assets of Orexo AB (publ) from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $490.60 Million | +488.44% |
| 2024-12-31 | $-126.30 Million | -314.43% |
| 2023-12-31 | $58.90 Million | -69.62% |
| 2022-12-31 | $193.90 Million | -44.54% |
| 2021-12-31 | $349.60 Million | -37.40% |
| 2020-12-31 | $558.50 Million | -20.94% |
| 2019-12-31 | $706.40 Million | +48.37% |
| 2018-12-31 | $476.10 Million | +44.67% |
| 2017-12-31 | $329.10 Million | +6.06% |
| 2016-12-31 | $310.30 Million | +14.88% |
| 2015-12-31 | $270.10 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Orexo AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 158050000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $490.60 Million | 100.00% |
| Total Equity | $490.60 Million | 100.00% |
Orexo AB (publ) Competitors by Market Cap
The table below lists competitors of Orexo AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chian Hsing Forging Industrial Co Ltd
TWO:4528
|
$23.41 Million |
|
Carlos Casado
BA:CADO
|
$23.41 Million |
|
HAVRF
PINK:HAVRF
|
$23.41 Million |
|
Dhunseri Investments Limited
NSE:DHUNINV
|
$23.41 Million |
|
Genetec Technology Bhd
KLSE:0104
|
$23.40 Million |
|
World Known MFG (Cayman) Limited
TW:4581
|
$23.40 Million |
|
Cyan AG
XETRA:CYR
|
$23.39 Million |
|
Optivision Technology
TWO:3666
|
$23.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Orexo AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -126,300,000 to 490,600,000, a change of 616,900,000.
- Net income of 639,300,000 contributed positively to equity growth.
- Other factors decreased equity by 22,400,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $639.30 Million | +130.31% |
| Other Changes | $-22.40 Million | -4.57% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Orexo AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $9.53 | $1.08 | x |
| 2018-12-31 | $13.78 | $1.08 | x |
| 2019-12-31 | $20.35 | $1.08 | x |
| 2020-12-31 | $16.29 | $1.08 | x |
| 2021-12-31 | $10.19 | $1.08 | x |
| 2022-12-31 | $5.64 | $1.08 | x |
| 2023-12-31 | $1.71 | $1.08 | x |
| 2024-12-31 | $-3.66 | $1.08 | x |
| 2025-12-31 | $14.14 | $1.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Orexo AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 130.31%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2458.85%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 2.66x
- Recent ROE (130.31%) is above the historical average (-23.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -77.75% | -32.50% | 0.63x | 3.78x | $-237.01 Million |
| 2016 | 9.35% | 4.11% | 0.69x | 3.28x | $-2.03 Million |
| 2017 | 7.05% | 3.60% | 0.64x | 3.05x | $-9.71 Million |
| 2018 | 28.96% | 17.61% | 0.61x | 2.70x | $90.29 Million |
| 2019 | 31.02% | 25.94% | 0.56x | 2.13x | $148.46 Million |
| 2020 | -15.11% | -12.72% | 0.54x | 2.21x | $-140.25 Million |
| 2021 | -63.93% | -39.56% | 0.44x | 3.64x | $-258.46 Million |
| 2022 | -91.59% | -28.45% | 0.56x | 5.72x | $-196.99 Million |
| 2023 | -217.83% | -20.08% | 0.81x | 13.35x | $-134.19 Million |
| 2024 | 0.00% | -683.50% | 0.05x | 0.00x | $-190.37 Million |
| 2025 | 130.31% | 2458.85% | 0.02x | 2.66x | $590.24 Million |
Industry Comparison
This section compares Orexo AB (publ)'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Orexo AB (publ) (ORXOF) | $490.60 Million | -77.75% | 1.66x | $23.41 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |